Stock Markets
Scilex reports growth in Q3 net sales for pain management products
PALO ALTO, Calif. – Scilex Holding Company (NASDAQ:SCLX), a company specializing in non-opioid pain management therapies, has announced preliminary unaudited financial results for the third quarter ending September 30, 2024. The company reported that net sales of ZTlido, its lidocaine topical product, were between $11.0 million and $13.0 million, marking an increase from $10.1 million in the same period the previous year. This growth represents an estimated 9% to 29% increase.
Total net sales of the company’s products for the quarter were also up, ranging from $12.0 million to $14.0 million, indicating a 19% to 39% rise compared to the $10.1 million reported in the third quarter of the previous year. These figures reflect the company’s ongoing efforts to expand its portfolio of pain management solutions.
Scilex’s commercial offerings include ZTlido for neuropathic pain associated with postherpetic neuralgia, ELYXYB for acute migraine treatment in adults, and Gloperba for the prophylaxis of gout flares. The company is also progressing with product candidates such as SP-102, a corticosteroid gel for sciatica pain, which has completed Phase 3 trials and received Fast Track designation from the FDA.
Despite the positive preliminary results, Scilex has cautioned that these figures are not yet finalized and are subject to change upon further review. The independent auditor has not reviewed or audited the preliminary estimated financial results, and the actual results may materially differ from these preliminary figures.
Investors are reminded that the information provided is based on a press release statement from Scilex Holding Company and that the company’s outlook is forward-looking and subject to various risks and uncertainties. These include market conditions, regulatory approvals, market acceptance of products, and the potential impact of COVID-19 or other disruptions.
Scilex Holding Company continues to focus on addressing unmet needs in pain management with non-opioid products, aiming to improve patient outcomes and capitalize on large market opportunities.
In other recent news, Scilex Holding has been actively managing its financial obligations and making strides in non-opioid pain management. The company recently secured a $50 million convertible note offering with key stakeholders such as Murchinson, 3i (LON:) LP, and Oramed Pharmaceuticals (NASDAQ:), Inc. This move is aimed at refinancing existing debt and bolstering long-term growth. Additionally, Scilex has extended a payment deadline in its agreement with Oramed Pharmaceuticals.
Scilex has also fulfilled a $10 million loan obligation through product delivery to FSF 33433 LLC, supplying specified quantities of its ZTlido product. In a separate transaction, institutional investors, including Oramed, are expected to acquire an 8% royalty on net sales of certain Scilex products, including ZTlido, for a total purchase price of $5 million.
The U.S. Food and Drug Administration has approved updates to the labeling of GLOPERBA®, a gout treatment, for precision dosing. This could potentially improve patient outcomes and adherence. Additionally, Scilex has received Drug Distributor Accreditation from the National Association of Boards of Pharmacy, enhancing its credentials in the pain management sector. These are the recent developments shaping the trajectory of Scilex Holding Company.
InvestingPro Insights
Scilex Holding Company’s (NASDAQ:SCLX) preliminary Q3 2024 results show promising growth in net sales, but a deeper look at the company’s financials reveals a more complex picture. According to InvestingPro data, Scilex’s revenue for the last twelve months as of Q2 2024 stood at $50.83 million, with a notable revenue growth of 30.11% in Q2 2024 compared to the previous quarter. This aligns with the positive trend seen in the preliminary Q3 results.
However, despite the sales growth, InvestingPro Tips highlight that Scilex is not currently profitable. The company’s operating income for the last twelve months was -$99.14 million, with an operating income margin of -195.02%. This suggests that while Scilex is expanding its top line, it’s still facing challenges in translating sales growth into profitability.
Another InvestingPro Tip indicates that Scilex’s valuation implies a strong free cash flow yield, which could be attractive to investors looking for potential value in the biotech sector. However, it’s worth noting that the company’s stock price has fallen significantly over the last three months, with a 51.29% decline according to InvestingPro data.
For investors seeking a more comprehensive analysis, InvestingPro offers additional tips and metrics that could provide further context to Scilex’s financial situation and market performance. There are 6 additional InvestingPro Tips available for SCLX, which could offer valuable insights for those considering an investment in this non-opioid pain management company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Stock Markets
Allbirds stock touches 52-week low at $7.65 amid market challenges
In a challenging market environment, Allbirds Inc. (NASDAQ:) stock has recorded a new 52-week low, dipping to $7.65. The eco-friendly footwear company has faced significant headwinds over the past year, reflected in a substantial 1-year change with a decline of -55.8%. Investors have shown concern as the brand navigates through a competitive retail landscape and supply chain issues, which have pressured the stock to its current low. The company’s efforts to rebound will be closely watched by market participants looking for signs of a turnaround or further indications of industry-wide pressures.
In other recent news, Allbirds disclosed its Q3 2024 financial results, reporting a net revenue of $43 million. This figure reflects a downturn due to reduced unit sales and transitions to a distributor model in certain regions. Despite these challenges, the company managed to increase its gross margin to 44.4%, attributed to lower freight costs and improved inventory management.
The company also launched two new products, the Tree Glider and Lounger Lift, which have been positively received by consumers. Allbirds revised its full-year revenue guidance to between $187 million and $193 million and anticipates an adjusted EBITDA loss of $75 million to $71 million.
Additionally, Allbirds has signed two new international distributor agreements, expanding its reach in Latin America and Europe from mid-2025. The company’s management, led by CEO Joe Vernachio and CFO Annie Mitchell, remains optimistic about future growth, driven by forthcoming product launches and strategic marketing efforts.
InvestingPro Insights
Allbirds Inc. (BIRD) continues to face significant challenges, as reflected in its recent stock performance and financial metrics. According to InvestingPro data, the company’s revenue growth has declined by 22.67% over the last twelve months as of Q3 2024, with a quarterly revenue decline of 24.89% in Q3 2024. This aligns with the InvestingPro Tip that analysts anticipate sales decline in the current year.
The company’s financial health is also concerning, with an operating income margin of -48.08% for the same period. An InvestingPro Tip highlights that Allbirds is quickly burning through cash, which is particularly worrisome given the current market conditions.
Despite these challenges, InvestingPro Tips indicate that Allbirds holds more cash than debt on its balance sheet and its liquid assets exceed short-term obligations. This could provide some financial flexibility as the company navigates its turnaround efforts.
For investors seeking a more comprehensive analysis, InvestingPro offers 17 additional tips for Allbirds, providing a deeper understanding of the company’s financial position and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Stock Markets
Quipt Home Medical stock hits 52-week low at $2.55
Quipt Home Medical (TASE:) Corp. (QIPT) stock has reached a new 52-week low, trading at $2.55. This latest price point marks a significant downturn for the company, which has experienced a 46.87% decline over the past year. Investors are closely monitoring the home medical equipment provider as it navigates through a challenging period marked by this notable decrease in stock value. The 52-week low serves as a critical indicator for the market, reflecting investor sentiment and potential shifts in the company’s financial health and operational performance.
In other recent news, Quipt Home Medical Corp has been making notable strides despite facing several challenges. The company’s third fiscal quarter report revealed a steady increase in revenue, reaching $64 million, a 6.1% rise from the previous year. The customer base also expanded by 9%, serving 153,223 unique patients, and adjusted EBITDA grew by 2.7% to $14.2 million.
Benchmark revised its stock price target for Quipt Home Medical, reducing it to $7 from the previous $9, but maintained a Buy rating for the stock. This adjustment was influenced by several factors including the expiration of Medicare’s 75/25 rate relief, a diminished Managed Care contract, and the repercussions of the Change Healthcare (NASDAQ:) cyberattack. However, the firm predicts that Quipt could achieve an 8%-10% organic growth rate by the second quarter of fiscal year 2025.
In the face of these challenges, Quipt Home Medical has reported a 9% increase in resupply revenue for sleep therapy and supplies, which accounts for half of the company’s revenues. The company’s management has also indicated an active mergers and acquisitions pipeline, which could provide further growth opportunities. These are the recent developments that investors should keep an eye on.
InvestingPro Insights
Despite Quipt Home Medical Corp. (QIPT) hitting a new 52-week low, InvestingPro data reveals some interesting insights that may provide context for investors. The company’s revenue growth remains strong, with a 29.31% increase over the last twelve months as of Q3 2024, reaching $244.23 million. This growth suggests that QIPT continues to expand its market presence in the home medical equipment sector.
However, profitability remains a concern. InvestingPro Tips highlight that QIPT has not been profitable over the last twelve months, with a negative P/E ratio of -24.61. On a more positive note, analysts predict that the company will become profitable this year, which could potentially reverse the stock’s downward trend.
The current market valuation implies a strong free cash flow yield, according to another InvestingPro Tip. This could indicate that the stock may be undervalued at its current price, especially considering that it’s trading near its 52-week low. Investors looking for a deeper analysis can find 7 additional InvestingPro Tips for QIPT, offering a more comprehensive view of the company’s financial situation and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Stock Markets
Muslims who voted for Trump upset by his pro-Israel cabinet picks
By Andrea Shalal
WASHINGTON (Reuters) – U.S. Muslim leaders who supported Republican Donald Trump to protest against the Biden administration’s support for Israel’s war on Gaza and attacks on Lebanon have been deeply disappointed by his Cabinet picks, they tell Reuters.
“Trump won because of us and we’re not happy with his Secretary of State pick and others,” said Rabiul Chowdhury, a Philadelphia investor who chaired the Abandon Harris campaign in Pennsylvania and co-founded Muslims for Trump. Muslim support for Trump helped him win Michigan and may have factored into other swing state wins, strategists believe.
Trump picked Republican senator Marco Rubio, a staunch supporter of Israel for Secretary of State. Rubio said earlier this year he would not call for a ceasefire in Gaza, and that he believed Israel should destroy “every element” of Hamas. “These people are vicious animals,” he added.
Trump also nominated Mike Huckabee, a former Arkansas governor and staunch pro-Israel conservative who backs Israeli occupation of the West Bank and has called a two state solution in Palestine “unworkable”, as the next ambassador to Israel.
He has picked Republican Representative Elise Stefanik, who called the UN a “cesspool of antisemitism” for its condemnation of deaths in Gaza, to serve as U.S. ambassador to the United Nations.
Rexhinaldo Nazarko, executive director of the American Muslim Engagement and Empowerment Network (AMEEN), said Muslim voters had hoped Trump would choose Cabinet officials who work toward peace, and there was no sign of that.
“We are very disappointed,” he said. “It seems like this administration has been packed entirely with neoconservatives and extremely pro-Israel, pro-war people, which is a failure on the on the side of President Trump, to the pro-peace and anti-war movement.”
Nazarko said the community would continue pressing to make its voices heard after rallying votes to help Trump win. “At least we’re on the map.”
Hassan Abdel Salam, a former professor at the University of Minnesota, Twin Cities and co-founder of the Abandon Harris campaign, which endorsed Green Party candidate Jill Stein, said Trump’s staffing plans were not surprising, but had proven even more extreme that he had feared.
“It’s like he’s going on Zionist overdrive,” he said. “We were always extremely skeptical…Obviously we’re still waiting to see where the administration will go, but it does look like our community has been played.”
The Trump campaign did not immediately respond to an email seeking comment.
Several Muslim and Arab supporters of Trump said they hoped Richard Grenell, Trump’s former acting director of national intelligence, would play a key role after he led months of outreach to Muslim and Arab American communities, and was even introduced as a potential next secretary of state at events.
Another key Trump ally, Massad Boulos, the Lebanese father-in-law of Trump’s daughter Tiffany, met repeatedly with Arab American and Muslim leaders.
Both promised Arab American and Muslim voters that Trump was a candidate for peace who would act swiftly to end the wars in the Middle East and beyond. Neither was immediately reachable.
Trump made several visits to cities with large Arab American and Muslim populations, include a stop in Dearborn, a majority Arab city, where he said he loved Muslims, and Pittsburgh, where he called Muslims for Trump “a beautiful movement. They want peace. They want stability.”
Rola Makki, the Lebanese American, Muslim vice chair for outreach of the Michigan Republican Party, shrugged off the criticism.
“I don’t think everyone’s going to be happy with every appointment Trump makes, but the outcome is what matters,” she said. “I do know that Trump wants peace, and what people need to realize is that there’s 50,000 dead Palestinians and 3,000 dead Lebanese, and that’s happened during the current administration.”
- Forex2 years ago
Forex Today: the dollar is gaining strength amid gloomy sentiment at the start of the Fed’s week
- Forex2 years ago
How is the Australian dollar doing today?
- Forex2 years ago
Dollar to pound sterling exchange rate today: Pound plummeted to its lowest since 1985
- Forex2 years ago
Unbiased review of Pocket Option broker
- Cryptocurrency2 years ago
What happened in the crypto market – current events today
- World2 years ago
Why are modern video games an art form?
- Commodities2 years ago
Copper continues to fall in price on expectations of lower demand in China
- Forex2 years ago
The dollar is down again against major world currencies